Benchmark Co. analyst Robert Wasserman maintained a Buy rating on Emergent Biosolutions (EBS – Research Report) yesterday and set a price target of $12.00.
Robert Wasserman has given his Buy rating due to a combination of factors including Emergent BioSolutions’ strong financial performance in the first quarter of 2025. The company reported revenues and earnings per share that exceeded expectations, driven by robust sales of their Smallpox medical countermeasure products. This performance, along with strategic new contracts and approvals, underscores the company’s solid market position.
Additionally, Emergent has significantly improved its financial health by reducing net debt and increasing liquidity, which positions it well for future growth opportunities such as mergers and acquisitions and share buybacks. The company’s guidance for the year remains optimistic, with expectations of increased orders and contributions from new agreements. These factors, along with the potential for long-term business development, support the Buy rating and a price target that suggests substantial upside from current levels.
EBS’s price has also changed dramatically for the past six months – from $11.770 to $6.360, which is a -45.96% drop .